Treatment(s) now being considered-Biological therapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Biological therapy Posts on Medivizor

Epidermal growth factor ointment improves the treatment of skin side effects in patients receiving treatment for colorectal cancer

Posted by on Sep 26, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with colorectal cancer receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some background...

Read More

Side effects of ado-trastuzumab emtansine impacting outcomes in patients with HER2+ advanced breast cancer

Posted by on Aug 25, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer.  This study concluded that these side effects do not impact the outcomes for these patients.   Some background...

Read More

Cetuximab improves the outcomes of previously untreated patients with metastatic colorectal cancer

Posted by on May 28, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of first-line treatment with cetuximab (Erbitux) and bevacizumab (Avastin) in advanced colorectal cancer. Researchers suggested that cetuximab is associated with better outcomes when compared to bevacizumab.    Some background Colorectal cancer is the third most common cancer worldwide....

Read More

Looking for patients with metastatic colorectal cancer to test a combined treatment

Posted by on Dec 31, 2018 in Colorectal cancer | 0 comments

In a nutshell This phase 3 trial is examining the effectiveness of a combination treatment with panitumumab (Vectibix), leucovorin and fluorouracil after chemotherapy combined with panitumumab in metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured is progression-free survival (PFS; time from treatment to...

Read More

Evaluating brentuximab vedotin after alloSCT in patients with recurrent Hodgkin Lymphoma

Posted by on Nov 8, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of brentuximab vedotin (Adcetris) treatment for patients with relapsed (recurrent) or progressive (tumor grows or spreads) Hodgkin’s lymphoma (HL) after allogeneic (allo) stem cell transplantation (SCT). This study concluded that brentuximab vedotin is safe and effective for these patients. Some...

Read More

Oral mucositis caused by targeted therapy for colorectal cancer: which drug is safer?

Posted by on Nov 4, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the frequency and severity of oral mucositis (OM) in patients with colorectal cancer treated with chemotherapy and panitumumab (Vectibix) or cetuximab (Erbitux). Researchers suggested that panitumumab ?is associated with increased levels of OM in these patients. Some background Colorectal cancer is the fourth...

Read More

Searching for patients with relapsed/refractory Hodgkin lymphoma to test BV-ICE treatment

Posted by on Aug 31, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is investigating the best dose and effectiveness of brentuximab vedotin (Adcetris) combined with ICE (ifosfamide, carboplatin, etoposide) for Hodgkin’s lymphoma (HL) patients with relapsed or refractory (not responding to treatment) disease. The main outcomes to be measured include the tolerated dose without unacceptable...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Read More

MOR208: a new antibody therapy for relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Jun 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of MOR208 in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma. This study concluded that MOR208 monotherapy was safe and showed promising results in these patients. Some background Chemoimmunotherapy is the current standard first-line...

Read More